Erik Pong

1.4k total citations
24 papers, 1.1k citations indexed

About

Erik Pong is a scholar working on Radiology, Nuclear Medicine and Imaging, Immunology and Molecular Biology. According to data from OpenAlex, Erik Pong has authored 24 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Radiology, Nuclear Medicine and Imaging, 13 papers in Immunology and 8 papers in Molecular Biology. Recurrent topics in Erik Pong's work include Monoclonal and Polyclonal Antibodies Research (22 papers), Chronic Lymphocytic Leukemia Research (8 papers) and T-cell and B-cell Immunology (7 papers). Erik Pong is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (22 papers), Chronic Lymphocytic Leukemia Research (8 papers) and T-cell and B-cell Immunology (7 papers). Erik Pong collaborates with scholars based in United States, Germany and South Korea. Erik Pong's co-authors include Seung Y. Chu, John R. Desjarlais, Sher Karki, Matthew J. Bernett, David E. Szymkowski, Gregory L. Moore, Holly M. Horton, Umesh S. Muchhal, Irene Leung and Greg A. Lazar and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Erik Pong

23 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Erik Pong United States	16	617	484	433	358	141	24	1.1k
Hsing Chen United States	12	541 0.9×	415 0.9×	331 0.8×	218 0.6×	30 0.2×	18	797
Thomas Beyer Germany	18	498 0.8×	780 1.6×	489 1.1×	309 0.9×	27 0.2×	28	1.3k
A W Harris Australia	9	174 0.3×	697 1.4×	500 1.2×	265 0.7×	84 0.6×	9	1.1k
C S Woodhouse United States	16	584 0.9×	390 0.8×	392 0.9×	343 1.0×	63 0.4×	23	1.0k
Marilyn Thien Australia	7	209 0.3×	856 1.8×	227 0.5×	153 0.4×	90 0.6×	14	1.3k
Mark W. Rixon United States	13	289 0.5×	566 1.2×	354 0.8×	74 0.2×	44 0.3×	25	1.1k
Lee K. Sun United States	11	360 0.6×	298 0.6×	292 0.7×	168 0.5×	54 0.4×	13	829
Hákan Mellstedt Sweden	23	466 0.8×	637 1.3×	350 0.8×	355 1.0×	215 1.5×	40	1.2k
Aniruddha Choudhury Sweden	20	185 0.3×	1.2k 2.4×	460 1.1×	909 2.5×	92 0.7×	38	1.7k
Mark W. Brunvand United States	15	124 0.2×	554 1.1×	375 0.9×	293 0.8×	176 1.2×	22	1.2k

Countries citing papers authored by Erik Pong

Since Specialization

Citations

This map shows the geographic impact of Erik Pong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik Pong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik Pong more than expected).

Fields of papers citing papers by Erik Pong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erik Pong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik Pong. The network helps show where Erik Pong may publish in the future.

Co-authorship network of co-authors of Erik Pong

This figure shows the co-authorship network connecting the top 25 collaborators of Erik Pong. A scholar is included among the top collaborators of Erik Pong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erik Pong. Erik Pong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Tian, Matthew S. Faber, Erik Pong, et al.. (2022). 1067 Synergistic combination of natural killer cell engagers (NKEs) with proinflammatory cytokines. Regular and Young Investigator Award Abstracts. A1109–A1109. 2 indexed citations

Bhat, Menakshi, Qian Wu, Erik Pong, et al.. (2021). Accelerated Clearance and Degradation of Cell-Free HIV by Neutralizing Antibodies Occurs via FcγRIIb on Liver Sinusoidal Endothelial Cells by Endocytosis. The Journal of Immunology. 206(6). 1284–1296. 6 indexed citations

Chu, Seung Y., Erik Pong, Christine Bonzon, et al.. (2020). Inhibition of B cell activation following in vivo co-engagement of B cell antigen receptor and Fcγ receptor IIb in non-autoimmune-prone and SLE-prone mice. SHILAP Revista de lepidopterología. 4. 100075–100075. 17 indexed citations

Nisthal, Alex, Matthew A. Dragovich, Erik Pong, et al.. (2020). Abstract 5663: Affinity tuned XmAb®2+1 PSMA x CD3 bispecific antibodies demonstrate selective activity in prostate cancer models. Cancer Research. 80(16_Supplement). 5663–5663. 1 indexed citations

Moore, Gregory L., Matthew J. Bernett, Rumana Rashid, et al.. (2018). A robust heterodimeric Fc platform engineered for efficient development of bispecific antibodies of multiple formats. Methods. 154. 38–50. 49 indexed citations

Chu, Seung Y., Erik Pong, Rumana Rashid, et al.. (2016). Abstract 5000: Immunotherapy with anti-PSMA x anti-CD3 bispecific antibody stimulates potent killing of a human prostate cancer cell line and target-mediated T cell activation in monkeys: A potential therapy for prostate cancer. Cancer Research. 76(14_Supplement). 5000–5000.

Chu, Seung Y., Erik Pong, Hsing Chen, et al.. (2014). Immunotherapy with Long-Lived Anti-CD123 × Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human AML Cell Lines and of CD123+ Cells in Monkeys: A Potential Therapy for Acute Myelogenous Leukemia. Blood. 124(21). 2316–2316. 34 indexed citations

Chu, Seung Y., Yvonne Miranda, Sheryl Phung, et al.. (2014). Immunotherapy with Long-Lived Anti-CD38 × Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human Myeloma Cell Lines and CD38+ Cells in Monkeys: A Potential Therapy for Multiple Myeloma. Blood. 124(21). 4727–4727. 14 indexed citations

Bernett, Matthew J., Seung Y. Chu, Irene Leung, et al.. (2013). Immune suppression in cynomolgus monkeys by XPro9523. mAbs. 5(3). 384–396. 22 indexed citations

10.

Chu, Seung Y., Erik Pong, Yvonne Miranda, et al.. (2013). Suppression of Rheumatoid Arthritis B Cells by XmAb5871, an Anti‐CD19 Antibody That Coengages B Cell Antigen Receptor Complex and Fcγ Receptor IIb Inhibitory Receptor. Arthritis & Rheumatology. 66(5). 1153–1164. 51 indexed citations

11.

Chu, Seung Y., Holly M. Horton, Erik Pong, et al.. (2012). Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody. Journal of Allergy and Clinical Immunology. 129(4). 1102–1115. 72 indexed citations

12.

Tai, Yu‐Tzu, Holly M. Horton, Sun‐Young Kong, et al.. (2012). Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function. Blood. 119(9). 2074–2082. 41 indexed citations

13.

Moore, Gregory L., Erik Pong, Duc-Hanh T. Nguyen, et al.. (2011). A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens. mAbs. 3(6). 546–557. 89 indexed citations

14.

Horton, Holly M., Seung Y. Chu, Erik Pong, et al.. (2011). Antibody-Mediated Coengagement of FcγRIIb and B Cell Receptor Complex Suppresses Humoral Immunity in Systemic Lupus Erythematosus. The Journal of Immunology. 186(7). 4223–4233. 112 indexed citations

15.

Bernett, Matthew J., Sher Karki, Gregory L. Moore, et al.. (2010). Engineering Fully Human Monoclonal Antibodies from Murine Variable Regions. Journal of Molecular Biology. 396(5). 1474–1490. 36 indexed citations

16.

Horton, Holly M., Matthew J. Bernett, Erik Pong, et al.. (2008). Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia. Cancer Research. 68(19). 8049–8057. 187 indexed citations

17.

Chu, Seung Y., Igor Voštiar, Sher Karki, et al.. (2008). Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcγRIIb with Fc-engineered antibodies. Molecular Immunology. 45(15). 3926–3933. 119 indexed citations

18.

Zhukovsky, Eugene A., Holly M. Horton, Matthias Peipp, et al.. (2008). An Fc-Engineered Humanized Anti-CD40 Monoclonal Antibody, XmAb5485, Exhibits Potent Activity in Vitro and in Vivo against Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma. Blood. 112(11). 881–881. 1 indexed citations

19.

Deng, Guoren, et al.. (2004). Promoter Methylation Inhibits APC Gene Expression by Causing Changes in Chromatin Conformation and Interfering with the Binding of Transcription Factor CCAAT-Binding Factor. Cancer Research. 64(8). 2692–2698. 51 indexed citations

20.

Deng, Guoren, Ada Chen, Erik Pong, & Young S. Kim. (2001). Methylation in hMLH1 promoter interferes with its binding to transcription factor CBF and inhibits gene expression. Oncogene. 20(48). 7120–7127. 71 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact